Kaissa O.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Phase 1 Evaluation of JNJ-87890387 in Patients with Advanced Solid Tumors
- Phase I Evaluation of NI-1801 Monotherapy and Combination with Anti-PD-1 or Paclitaxel in Advanced Mesothelin-Expressing Solid Tumors
- Phase 1 Evaluation of Tarlatamab Safety, Tolerability, and Pharmacokinetics in Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 64 of 179 partner sites.
Specializations
Breast Cancer Research
Specialized focus on advanced breast cancer variants including triple negative breast cancer, hormone receptor positive breast cancer, and HER2-expressing breast cancers. Particular emphasis on metastatic cases requiring innovative therapeutic approaches.
- Metastatic Disease Management
- HER2-Targeted Therapies
- Triple Negative Treatment Solutions
Advanced Solid Tumors
Extensive work with diverse solid malignancies, particularly focusing on PRAME-positive cancers and PIWIL1-positive tumors. Investigates novel therapeutic approaches for treatment-resistant cases.
- Targeted Molecular Therapies
- Immunotherapy Applications
- Biomarker-Driven Treatment
Specialized Cancer Types
Focused expertise in treating small cell lung cancer, esophageal squamous cell carcinoma, and head and neck cancers. Additional experience with mesothelin-expressing malignancies.
- Lung Cancer Therapeutics
- Head and Neck Oncology
- Gastrointestinal Cancers
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.